Sanofi Other Current Assets 2012-2026 | SNY
Sanofi other current assets from 2012 to 2026. Other current assets can be defined as field containing the sum of all current assets that cannot be standardized into another field as well as those that are aggregated by the company because materially, they are too small to list separately.
- Sanofi other current assets for the quarter ending March 31, 2026 were $0M, a 0% increase year-over-year.
- Sanofi other current assets for 2024 were $4.14B, a 10.24% increase from 2023.
- Sanofi other current assets for 2023 were $3.756B, a 0.92% increase from 2022.
- Sanofi other current assets for 2022 were $3.721B, a 11.92% decline from 2021.
|
Sanofi Annual Other Current Assets (Millions of US $) |
|
|---|---|
| 2024 | $4,140 |
| 2023 | $3,756 |
| 2022 | $3,721 |
| 2021 | $4,225 |
| 2020 | $4,506 |
| 2019 | $3,643 |
| 2018 | $3,445 |
| 2017 | $2,266 |
| 2016 | $2,447 |
| 2015 | $1,962 |
| 2014 | $2,867 |
| 2013 | $3,038 |
| 2012 | $3,029 |
| 2011 | $3,437 |
|
Sanofi Quarterly Other Current Assets (Millions of US $) |
|
|---|---|
| 2026-03-31 | |
| 2025-12-31 | $4,600 |
| 2025-09-30 | |
| 2025-06-30 | $4,081 |
| 2025-03-31 | |
| 2024-12-31 | $4,140 |
| 2024-09-30 | |
| 2024-06-30 | $4,168 |
| 2024-03-31 | |
| 2023-12-31 | $3,756 |
| 2023-09-30 | |
| 2023-06-30 | $3,676 |
| 2023-03-31 | |
| 2022-12-31 | $3,721 |
| 2022-09-30 | |
| 2022-06-30 | |
| 2022-03-31 | |
| 2021-09-30 | |
| 2021-03-31 | |
| 2020-09-30 | |
| 2020-03-31 | |
| 2019-09-30 | |
| 2019-03-31 | |
| 2018-03-31 | |
| 2017-12-31 | $2,266 |
| 2017-09-30 | |
| 2017-06-30 | $2,301 |
| 2017-03-31 | |
| 2016-12-31 | $2,447 |
| 2016-09-30 | |
| 2016-06-30 | $2,002 |
| 2016-03-31 | |
| 2015-09-30 | |
| 2015-06-30 | $2,400 |
| 2014-06-30 | $2,845 |
| 2013-06-30 | $2,714 |
| 2012-06-30 | $2,606 |
| 2012-03-31 | |
| 2011-12-31 | $3,437 |
| 2011-09-30 | |
| 2011-06-30 | $2,892 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $114.048B | $49.347B |
| Sanofi-Aventis manufactures & markets prescription drugs across countries. It focuses on major therapeutic areas such as multiple sclerosis, cardiovascular, immunology, neurology, oncology, rare blood disorders & diabetes, etc. By taking Genzyme Corporation as a subsidiary, it added products like Cerezyme, Myozyme/Lumizyme & Fabrazyme to its portfolio. Sanofi has become a major player in the CHC sector. It acquired many companies i.e. Ablynx & Bioverativ, Synthorx & Principia & Translate Bio and Kadmon. It has collaborated with companies like Regeneron among others. It develops and markets Dupixent, Kevzara & Libtayo in collaboration with Regeneron. Sanofi, along with Regeneron, is now solely responsible for Praluent marketing in & outside the U.S. Sanofi operates through 3 Global Business Units: Specialty Care (neurology & immunology, rare diseases, rare blood disorders & oncology), Vaccines & General Medicines (diabetes, cardiovascular & established products) and Consumer Healthcare, a standalone unit. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $887.629B | 38.81 |
| Johnson & Johnson (JNJ) | United States | $574.358B | 22.08 |
| AbbVie (ABBV) | United States | $367.673B | 20.79 |
| Roche Holding AG (RHHBY) | Switzerland | $318.782B | 0.00 |
| Merck (MRK) | United States | $299.893B | 13.54 |
| Novartis AG (NVS) | Switzerland | $293.951B | 17.16 |
| Novo Nordisk (NVO) | Denmark | $167.527B | 9.60 |
| Pfizer (PFE) | United States | $153.074B | 8.33 |
| Bayer (BAYRY) | Germany | $46.178B | 8.70 |
| Innoviva (INVA) | United States | $1.760B | 5.88 |